Triple-negative breast cancer (TNBC), which lacks estrogen receptor (ER) and progesterone receptor (PR) expression as well as human epidermal growth factor receptor 2 (HER2) amplification, is one of the most difficult breast cancers to treat because there is no targeted treatment [1, 2]. Here, ESR1 is linked to triple-negative breast carcinoma.